<DOC>
	<DOCNO>NCT01594684</DOCNO>
	<brief_summary>In stent restenosis peripheral artery disease ( superficial popliteal artery ) either treat uncoated paclitaxel coat balloon .</brief_summary>
	<brief_title>Cotavance™ Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty Treatment In-stent Restenosis SFA Popliteal Arteries</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Instent restenosis reocclusion target lesion due interventional treatment &gt; 3 month prior enrollment . 2 . Has evidence ≥ 70 % stenosis occlusion SFA and/or popliteal confirm angiography 327 cm long . 3 . Reference vessel diameter 3 7 mm ( reference vessel diameter = normal vessel diameter 1 cm proximal index lesion ) 4 . Patients ( men woman ) PAD disease category 2 5 accord Rutherford classification . 5 . Patient eligible operative vascular intervention case complication procedure . 6 . Female patient child bear potential must negative pregnancy test 7 day theprior time intervention . 7 . Fully inform sign consent must obtain patient . 8 . Patients must willing able continue study participation follow study procedure order ensure completion procedure observation require protocol . 9 . Patient evidence least one run vessel also require treatment significant ( ≥ 50 % stenosis occlusion ) stenosis index procedure ankle/foot limb treat . Treatment infrapopliteal lesion must stag least 30 day index procedure . 10 . If restnosis occur arm 30 day later ( reresternosis ) treament two drug elute balloon location ( double dose ) 1 . Patients two lesion target vessel require treatment ( distance two lesion less 2 cm , lesion count one lesion ) . The second lesion also treat either coat uncoated balloon ( accord randomization ) 2 . Guidewire cross lesion and/or intentional subintimal approach stented lesion require . 3 . Patients stent fracture grade 24 . 4 . Inflow lesion ( proximal study lesion ) flow limitation successfully treat prior treatment study lesion . 5 . Acute thrombosis study lesion require lysis thrombectomy prior treatment study lesion . 6 . Acutely occur symptom lysis operation therapeutic option within last 6 week within study limb . 7 . Potential loss leg due critical acute ischemia . 8 . No patent distal runoff vessel . 9 . Aneurysm blood vessel intend intervention study . 10 . Blood platelet count &lt; 100.000/mm3 &gt; 700.000/mm3 , leukocyte count &lt; 3.000/mm3 . 11 . Contraindication anticoagulation , antiplatelet agent ( e.g . aspirin , heparin , clopidogrel , ticlopidine , abciximab ) , paclitaxel . 12 . Known intolerance contraindication ( e.g . severe hepatic ( ALAT and/or ASAT &gt; 3 time normal reference range ) renal ( creatinine &gt; 1.1 mg/dl woman &gt; 1.5 mg/dl men ) contrast agent adequately pretreated , e.g . adequate hydration . 13 . Severe illness cancer , liver renal disease , myocardial insufficiency lead protocol deviation and/or reduce life expectancy le 2 year . 14 . Manifest hyperthyreosis . 15 . Latent hyperthyreosis without adequate therapy , e.g. , previous block Natriumperchlorat ( Irenat® ) . 16 . Significant gastrointestinal hemorrhage within previous 6 month prior study participation . 17 . History hemorrhagic diathesis coagulopathy rejection blood transfusion . 18 . Medical reason double antiplatelet therapy anticoagulated patient , e.g. , receive coumadine . 19 . Any severe medical condition might interfere interpretation data result unacceptable risk patient 's participation study , accord judgment clinical investigator . 20 . Female patient pregnant lactating . 21 . Patient 18 year age . 22 . Participation another clinical study 30 day prior study entry . 23 . Previous participation trialstudy ( one leg treat within study ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>restenosis</keyword>
	<keyword>stent</keyword>
	<keyword>drug eltuing balloon</keyword>
	<keyword>peripheral arterial disease</keyword>
</DOC>